MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.51
-1.30
-2.84%
After Hours: 44.51 0 0.00% 16:00 01/24 EST
OPEN
46.24
PREV CLOSE
45.81
HIGH
46.34
LOW
44.25
VOLUME
533.51K
TURNOVER
--
52 WEEK HIGH
64.48
52 WEEK LOW
42.48
MARKET CAP
2.23B
P/E (TTM)
4.124
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARNA News

  • Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
  • Zacks.01/17 13:16
  • FDA Grants Fast Track Designation To Arena Pharmaceuticals' APD418 For Development In Decompensated Heart Failure Patients
  • Benzinga.01/16 14:00
  • FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
  • PR Newswire.01/16 14:00
  • Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
  • PR Newswire.01/13 21:01

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ARNA

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More

Webull offers Arena Pharmaceuticals, Inc. (ARNA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.